Skip to content
Assyro AI
Orange Book drug · Brand (NDA)

Slynd

Drospirenone

RLDNDA 211367 Exeltis USA Inc
Approved
May 23, 2019
Strengths
1
Listed patents
15

What does the FDA Orange Book show for Slynd?

Slynd contains Drospirenone and is the new drug FDA Orange Book record for NDA 211367. The application has 1 presentation with strength, dosage-form, route, status, RLD/RS, TE, patent, and exclusivity context. Current inventory and clinical labeling are not established without an application-matched source.

FDA application
NDA 211367

New drug application identity from the Orange Book snapshot.

Application holder
Exeltis USA Inc

The listed applicant holds the FDA application; this field does not establish the product manufacturer.

Product presentations
1

Each FDA product number remains tied to its own strength, dosage form, route, and status.

Marketing categories
Prescription

Orange Book marketing categories do not establish real-time inventory or commercial availability.

Reference roles
RLD / RS

RLD and RS designations are presentation-specific, not inferred from the trade name.

TE codes
None posted

Therapeutic-equivalence codes apply only within the matching Orange Book product heading.

Listed patents
15

A zero means none appear in this snapshot, not that no patent rights exist.

Exclusivity records
0

FDA exclusivity and listed patent protection are distinct regulatory concepts.

Sourced from the official FDA Orange Book data file · snapshot refreshed

FDA product-presentation matrix

Every product number in this exact application
Every FDA product presentation under this application, with strength, dosage form and route, marketing status, therapeutic-equivalence code, and reference role.
ProductStrengthDosage form / routeMarketing statusTE codeReference role
0014MGTABLETORALPrescriptionNone posted
RLDRS

Marketing status, TE code, RLD, and RS are presentation-level fields. Never transfer one product number's designation to another presentation.

Who is responsible for this application?

Application holder is not the same as manufacturer

FDA application holder

Exeltis USA Inc

The Orange Book identifies this organization as the applicant responsible for NDA 211367.

Manufacturer status

Not established by the Orange Book

A product-specific FDA label or NDC source must independently identify a manufacturer, labeler, distributor, packager, repackager, or relabeler. The applicant name is not used as a substitute for that evidence.

Regulatory interpretation

What the record means, and what it does not
FDA marketing status

1 presentation listed as prescription

RX and OTC are Orange Book marketing categories, not real-time inventory signals. Confirm current commercial availability with labeling, the application holder, or an authoritative drug listing.

Therapeutic equivalence

No TE code is posted for this application

No TE code does not mean FDA found the product ineffective or non-equivalent. FDA generally publishes TE evaluations for multisource prescription products; single-source and some other products may have no code.

Patent & exclusivity record

15 listed patent expirations and 0 exclusivity dates remain on or after Jul 26, 2026

The latest future date recorded across those files is Jun 28, 2031. Patent and FDA exclusivity operate independently, can overlap, and do not by themselves predict a generic launch date.

Same-ingredient landscape

0 other ANDAs and 1 other NDA found

0 of the related ANDA applications are not marked discontinued. Sharing an ingredient does not establish pharmaceutical or therapeutic equivalence; strength, dosage form, route, and TE group still matter.

Which products are meaningfully comparable?

Exact ingredient + dosage form + route cohorts

NDA 211367 appears in 1 comparison cohort. These groups narrow the same-ingredient landscape, but strength and TE code must still match before interpreting therapeutic equivalence.

Tablet · Oral

Drospirenone

1 application
Product rows
1
Active applications
1
Active with AB row
0

Why are clinical sections unavailable?

Exact application-label matching status
Exact source match queuedQueue NDA-211367

No exact application-level FDA or DailyMed label match has been reviewed for this application. Approved uses, dosing, warnings, adverse reactions, and clinical evidence remain unavailable rather than being inherited from a related brand, generic, or ingredient record.

Until an exact application match passes human review, this page intentionally omits approved uses, dosing, warnings, adverse reactions, mechanism, and clinical-study summaries. It never inherits those claims from an RLD, brand, generic, or same-ingredient product.

Product detail

NDA 211367
RLDRS
Strength
4MG
Dosage form
TABLET
Route
ORAL
Marketing status
Prescription

Key dates

Approval, patents, exclusivity

  1. Approval

    FDA approval date of this drug product.

    7 yr 3 mo ago

  2. Today

  3. Patent 10179140 expires

    Listed method-of-use patent (U-2553) expiration.

    in 5 yr

  4. Patent 10603281 expires

    Listed method-of-use patent (U-2553) expiration.

    in 5 yr

  5. Patent 10849857 expires

    Listed drug product patent expiration.

    in 5 yr

  6. Patent 10987364 expires

    Listed drug product patent expiration.

    in 5 yr

  7. Patent 11123299 expires

    Listed drug product patent expiration.

    in 5 yr

  8. Patent 11291632 expires

    Listed drug product patent expiration.

    in 5 yr

  9. Patent 11291633 expires

    Listed drug product patent expiration.

    in 5 yr

  10. Patent 11351122 expires

    Listed drug product patent expiration.

    in 5 yr

  11. Patent 11413249 expires

    Listed method-of-use patent (U-2553) expiration.

    in 5 yr

  12. Patent 11478487 expires

    Listed drug product patent expiration.

    in 5 yr

  13. Patent 11504334 expires

    Listed drug product patent expiration.

    in 5 yr

  14. Patent 11951213 expires

    Listed method-of-use patent (U-2553) expiration.

    in 5 yr

  15. Patent 12090231 expires

    Listed method-of-use patent (U-2553) expiration.

    in 5 yr

  16. Patent 12280151 expires

    Listed drug product patent expiration.

    in 5 yr

  17. Patent 9603860 expires

    Listed method-of-use patent (U-2553) expiration.

    in 5 yr

Patent & exclusivity timeline

Protection horizon
2026202720282029203020312032TodayPatent 10179140: 2031-06-28Patent 10179140Patent 10603281: 2031-06-28Patent 10603281Patent 10849857: 2031-06-28Patent 10849857Patent 10987364: 2031-06-28Patent 10987364Patent 11123299: 2031-06-28Patent 11123299Patent 11291632: 2031-06-28Patent 11291632Patent 11291633: 2031-06-28Patent 11291633Patent 11351122: 2031-06-28Patent 11351122Patent 11413249: 2031-06-28Patent 11413249Patent 11478487: 2031-06-28Patent 11478487Patent 11504334: 2031-06-28Patent 11504334Patent 11951213: 2031-06-28Patent 11951213Patent 12090231: 2031-06-28Patent 12090231Patent 12280151: 2031-06-28Patent 12280151Patent 9603860: 2031-06-28Patent 9603860
Patent expiryExclusivity endToday

Pharmaceutical detail

FDA product record

Active ingredient

DROSPIRENONE

Strength

4MG

Dosage form

TABLET

Route

ORAL

TE code

Not listed

Application

NDA 211367

Product number

001

Marketing status

Prescription

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Listed patents

Orange Book patent file
Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10179140in 5 yr
U-2553
10603281in 5 yr
U-2553
10849857in 5 yr
ProductU-2553
10987364in 5 yr
Product
11123299in 5 yr
Product
11291632in 5 yr
Product
11291633in 5 yr
Product
11351122in 5 yr
Product
11413249in 5 yr
U-2553
11478487in 5 yr
Product
11504334in 5 yr
Product
11951213in 5 yr
U-2553
12090231in 5 yr
U-2553
12280151in 5 yr
Product
9603860in 5 yr
U-2553

Active-ingredient family

Brand + generics

This is a reference-listed drug (RLD), the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

View full Drospirenone family

How to use this record responsibly

Scope, limitations, and primary sources

What to verify before making a decision

  • The applicant is the holder of legal responsibility for the application; the Orange Book does not establish that the applicant manufactured or currently markets every listed product.
  • RX, OTC, and discontinued are FDA listing categories, not real-time pharmacy inventory or commercial-availability data.
  • Therapeutic equivalence applies only within the matching ingredient, dosage form, route, strength, and TE-code group; same ingredient alone is insufficient.
  • Listed patent and exclusivity dates are regulatory intelligence, not legal advice, a freedom-to-operate analysis, or a reliable generic-launch forecast.
  • The Orange Book is not prescribing information and does not provide indications, dosing, contraindications, adverse reactions, recalls, or current safety communications.

Official FDA references

Data shown here is normalized for search and comparison. When a regulatory, substitution, launch, or legal decision turns on a field, verify it against the current FDA record and the relevant source document.

Slynd: frequently asked questions

Approval, therapeutic equivalence, patents, and exclusivity for this drug, from the FDA Orange Book.

Built directly from the FDA Orange Book product, patent, and exclusivity files refreshed Jul 02, 2026, 06:34 PM. Every strength of NDA 211367 is shown on this page. Interpret patents, exclusivity, availability, and therapeutic equivalence using the limitations above.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo